H.C. Wainwright lowered the firm’s price target on iTeos Therapeutics (ITOS) to $21 from $46 and keeps a Buy rating on the shares. The firm removed expected revenue from inupadenant in lung cancer following the interim data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS: